header image

News

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

31.08.2017

Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with...

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients

23.08.2017

Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously...

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with Von Willebrand disease (VWD) and haemophilia A

11.07.2017

Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors...

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

10.07.2017

Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress,...

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

06.07.2017

Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress...

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

22.05.2017

Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium

07.04.2017

HOBOKEN, N.J. (April 7, 2017) – Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island....

Page 1 Page 2 next